Abemaciclib is synergistic with doxorubicin in osteosarcoma pre-clinical models via inhibition of CDK4/6 –Cyclin D–Rb pathway

ConclusionsOur pre-clinical evidence provides a rationale of initializing clinical trial of investigating the efficacy of abemaciclib in combination with doxorubicin in osteosarcoma patients. Our work also highlights the therapeutic value of CDK4/6 inhibition in osteosarcoma with proper function of Rb.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research